These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 27317888)
1. Insights into (S)-rivastigmine inhibition of butyrylcholinesterase (BuChE): Molecular docking and saturation transfer difference NMR (STD-NMR). Bacalhau P; San Juan AA; Goth A; Caldeira AT; Martins R; Burke AJ Bioorg Chem; 2016 Aug; 67():105-9. PubMed ID: 27317888 [TBL] [Abstract][Full Text] [Related]
2. Tailored Modeling of Rivastigmine Derivatives as Dual Acetylcholinesterase and Butyrylcholinesterase Inhibitors for Alzheimer's Disease Treatment. Adeowo FY; Oyetunji TP; Ejalonibu MA; Ndagi U; Kumalo HM; Lawal MM Chem Biodivers; 2021 Nov; 18(11):e2100361. PubMed ID: 34547176 [TBL] [Abstract][Full Text] [Related]
3. Discovery of Novel Pyrazolopyrimidinone Derivatives as Phosphodiesterase 9A Inhibitors Capable of Inhibiting Butyrylcholinesterase for Treatment of Alzheimer's Disease. Yu YF; Huang YD; Zhang C; Wu XN; Zhou Q; Wu D; Wu Y; Luo HB ACS Chem Neurosci; 2017 Nov; 8(11):2522-2534. PubMed ID: 28783948 [TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, biological evaluation, and molecular modeling studies of chalcone-rivastigmine hybrids as cholinesterase inhibitors. Wang L; Wang Y; Tian Y; Shang J; Sun X; Chen H; Wang H; Tan W Bioorg Med Chem; 2017 Jan; 25(1):360-371. PubMed ID: 27856236 [TBL] [Abstract][Full Text] [Related]
5. Synthesis, structural characterization, docking, lipophilicity and cytotoxicity of 1-[(1R)-1-(6-fluoro-1,3-benzothiazol-2-yl)ethyl]-3-alkyl carbamates, novel acetylcholinesterase and butyrylcholinesterase pseudo-irreversible inhibitors. Pejchal V; Štěpánková Š; Pejchalová M; Královec K; Havelek R; Růžičková Z; Ajani H; Lo R; Lepšík M Bioorg Med Chem; 2016 Apr; 24(7):1560-72. PubMed ID: 26947959 [TBL] [Abstract][Full Text] [Related]
6. Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson's disease dementia. Kandiah N; Pai MC; Senanarong V; Looi I; Ampil E; Park KW; Karanam AK; Christopher S Clin Interv Aging; 2017; 12():697-707. PubMed ID: 28458525 [TBL] [Abstract][Full Text] [Related]
7. New cholinesterase inhibitors for Alzheimer's disease: Structure Activity Studies (SARs) and molecular docking of isoquinolone and azepanone derivatives. Bacalhau P; San Juan AA; Marques CS; Peixoto D; Goth A; Guarda C; Silva M; Arantes S; Caldeira AT; Martins R; Burke AJ Bioorg Chem; 2016 Aug; 67():1-8. PubMed ID: 27231829 [TBL] [Abstract][Full Text] [Related]
8. Nature-based molecules combined with rivastigmine: A symbiotic approach for the synthesis of new agents against Alzheimer's disease. Nesi G; Chen Q; Sestito S; Digiacomo M; Yang X; Wang S; Pi R; Rapposelli S Eur J Med Chem; 2017 Dec; 141():232-239. PubMed ID: 29031070 [TBL] [Abstract][Full Text] [Related]
9. Tricyclic pyrazolo[1,5-d][1,4]benzoxazepin-5(6H)-one scaffold derivatives: Synthesis and biological evaluation as selective BuChE inhibitors. Chen SC; Qiu GL; Li B; Shi JB; Liu XH; Tang WJ Eur J Med Chem; 2018 Mar; 147():194-204. PubMed ID: 29438888 [TBL] [Abstract][Full Text] [Related]
10. In silico, NMR and pharmacological evaluation of an hydroxyoxindole cholinesterase inhibitor. Bacalhau P; Fernandes L; Rosário Martins M; Candeias F; Carreiro EP; López Ó; Teresa Caldeira A; Totobenazara J; Guedes RC; Burke AJ Bioorg Med Chem; 2019 Jan; 27(2):354-363. PubMed ID: 30578075 [TBL] [Abstract][Full Text] [Related]
11. Combined QSAR, molecular docking and molecular dynamics study on new Acetylcholinesterase and Butyrylcholinesterase inhibitors. Daoud I; Melkemi N; Salah T; Ghalem S Comput Biol Chem; 2018 Jun; 74():304-326. PubMed ID: 29747032 [TBL] [Abstract][Full Text] [Related]
12. Novel carbamate derivatives as selective butyrylcholinesterase inhibitors. Bajda M; Łątka K; Hebda M; Jończyk J; Malawska B Bioorg Chem; 2018 Aug; 78():29-38. PubMed ID: 29529519 [TBL] [Abstract][Full Text] [Related]
13. Novel Iodinated Hydrazide-hydrazones and their Analogues as Acetyl- and Butyrylcholinesterase Inhibitors. Krátký M; Štěpánková Š; Brablíková M; Svrčková K; Švarcová M; Vinšová J Curr Top Med Chem; 2020; 20(23):2106-2117. PubMed ID: 32814531 [TBL] [Abstract][Full Text] [Related]
14. N-[3,5-Bis(trifluoromethyl)phenyl]-5-bromo-2-hydroxybenzamide Analogues: Novel Acetyl- and Butyrylcholinesterase Inhibitors. Krátký M; Jaklová K; Štěpánková Š; Svrčková K; Pflégr V; Vinšová J Curr Top Med Chem; 2020; 20(23):2094-2105. PubMed ID: 32814530 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit. Giacobini E; Spiegel R; Enz A; Veroff AE; Cutler NR J Neural Transm (Vienna); 2002 Jul; 109(7-8):1053-65. PubMed ID: 12111443 [TBL] [Abstract][Full Text] [Related]
16. Novel ferulic amide derivatives with tertiary amine side chain as acetylcholinesterase and butyrylcholinesterase inhibitors: The influence of carbon spacer length, alkylamine and aromatic group. Liu H; Liu L; Gao X; Liu Y; Xu W; He W; Jiang H; Tang J; Fan H; Xia X Eur J Med Chem; 2017 Jan; 126():810-822. PubMed ID: 27951489 [TBL] [Abstract][Full Text] [Related]
17. Highly potent and selective aryl-1,2,3-triazolyl benzylpiperidine inhibitors toward butyrylcholinesterase in Alzheimer's disease. de Andrade P; Mantoani SP; Gonçalves Nunes PS; Magadán CR; Pérez C; Xavier DJ; Hojo ETS; Campillo NE; Martínez A; Carvalho I Bioorg Med Chem; 2019 Mar; 27(6):931-943. PubMed ID: 30765302 [TBL] [Abstract][Full Text] [Related]
18. Synthesis, Biological Evaluation and Molecular Docking Study of Hydrazone-Containing Pyridinium Salts as Cholinesterase Inhibitors. Parlar S; Bayraktar G; Tarikogullari AH; Alptüzün V; Erciyas E Chem Pharm Bull (Tokyo); 2016; 64(9):1281-7. PubMed ID: 27581632 [TBL] [Abstract][Full Text] [Related]
19. Synthesis of some new 3-coumaranone and coumarin derivatives as dual inhibitors of acetyl- and butyrylcholinesterase. Alipour M; Khoobi M; Nadri H; Sakhteman A; Moradi A; Ghandi M; Foroumadi A; Shafiee A Arch Pharm (Weinheim); 2013 Aug; 346(8):577-87. PubMed ID: 23852709 [TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and biological evaluation of tricyclic pyrazolo[1,5-c][1,3]benzoxazin-5(5H)-one scaffolds as selective BuChE inhibitors. Qiu GL; He SS; Chen SC; Li B; Wu HH; Zhang J; Tang WJ J Enzyme Inhib Med Chem; 2018 Dec; 33(1):1506-1515. PubMed ID: 30284486 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]